In 2009, there will be an estimated 8,000 new cases of testicular cancer resulting in approximately 350 deaths in the United States. For reasons that remain unclear, the incidence of testicular cancer, the most common solid malignancy in men between the ages of 20 and 35 years, is increasing in both the United States and Europe. Given the dramatic improvements in survival rates from approximately 60% in the 1960s to over 90% at present, the management of testicular cancer has come to represent a model of the successful multidisciplinary approach to solid tumors. Although testicular cancer is highly curable, it requires appropriate management for patients of all stages, because both the cure rates and morbidity are highly sensitive to nuances in treatment.
展开▼
